When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition. This decision is based on the member’s current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.
This Medical Policy Bulletin document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy Bulletin will be reviewed regularly and be updated as scientific and medical literature becomes available. For more information on how Medical Policy Bulletins are developed, go to the About This Site section of this Medical Policy Web site.
Catalona PJ TM, Weiss R, Rimash T. The MicroFlow Spacer: A drug-eluting stent for the ethmoid sinus. Indian J Otolaryngol Head Neck Surg. 2011;63(3):258.
Cote DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. 2010;120(6):1269-1273.
Forwith KD, Chandra RK, Yun PT, et al. ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants. Laryngoscope. 2011;121(11):2473-2480.
Freeman SR, Sivayoham ES, Jepson K, et al. A preliminary randomised controlled trial evaluating the efficacy of saline douching following endoscopic sinus surgery. Clin Otolaryngol.2008;33(5):462-465.
Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis. Int Forum Allergy Rhinol.Nov 2014;4(11):861-870.
Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
Lavigne F, Miller SK, Gould AR, et al. Steroid-eluting sinus implant for in-office treatment of recurrent nasal polyposis: a prospective, multicenter study. Int Forum Allergy Rhinol. 2014;4(5):381-389.
Lee JM, Grewal A. Middle meatal spacers for the prevention of synechiae following endoscopic sinus surgery: a systematic review and meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol. May 30 2012.
Marple BF, Smith TL, Han JK, et al. Advance II: A Prospective, Randomized Study Assessing Safety and Efficacy of Bioabsorbable Steroid-Releasing Sinus Implants. Otolaryngol Head Neck Surg. 2012;146(6):1004-1011.
Matheny KE, Carter KB, Jr., Tseng EY, et al. Safety, feasibility, and efficacy of placement of steroid-eluting bioabsorbable sinus implants in the office setting: a prospective case series. Int Forum Allergy Rhinol.2014;4(10):808-815.
Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol. 2011;1(1):23-32.
Ow R, Groppo E, Clutter D, et al. Steroid-eluting sinus implant for in-office treatment of recurrent polyposis: a pharmacokinetic study. Int Forum Allergy Rhinol. Sep 25 2014.
Rotenberg BW, Zhang I, Arra I, et al. Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial. Laryngoscope. 2011;121(12):2702-2705.
Rudmik L MJ, Mechor B. Effect of a dexamethasone SinuFoam middle meatal spacer on endoscopic sinus surgery outcomes: A randomized, double-blind, placebo-controlled trial. Int Forum Allergy Rhinol. December. Epub ahead of print.
Steroid-eluting implant (Propel) for maintaining sinus patency after ethmoid sinus surgery. Plymouth Meeting (PA): ECRI Institute; 2015 February. (Emerging technology report). Also available: http://www.ecri.org.
Stewart AE, Vaughan WC. Balloon sinuplasty versus surgical management of chronic rhinosinusitis.Curr Allergy Asthma Rep. 2010;10(3):181–187.
US Food and Drug Administration (FDA). Center for Devices and Radiological Health (CDRH). Premarket Approval (PMA) Supplement. Decision Date 10/08/2014. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=353825 Accessed January 19, 2018.
US Food and Drug Administration (FDA). Center for Devices and Radiological Health (CDRH). PROPEL®. 510(k) summary. [FDA Web site]. 08/11/2011. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044b.pdf Accessed January 19, 2018.
US Food and Drug Administration (FDA). Center for Devices and Radiological Health (CDRH).PROPEL® Mini Sinus Implant. 510(k) summary. [FDA Web site]. 03/23/2016. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044S018b.pdf. Accessed January 19, 2018.
J7401 Mometasone furoate sinus implant, 10 micrograms